Cinacalcet May Lower Death Risk in Dialysis Subgroups
Researchers found lower all-cause mortality for cinacalcet-treated patients concomitantly treated with vitamin D and phosphate binders, for example.
Cinacalcet treatment is associated with decreased overall and cardiovascular mortality among younger dialysis patients and those with moderate secondary hyperparathyroidism (SHPT) and who do not have diabetes, researchers reported online in the European Journal of International Medicine.
Claudia Friedl, MD, of the Medical University of Graz, Graz, Austria, and colleagues studied 7983 dialysis patients, of whom 1572 (19.7%) were prescribed cinacalcet. A total of 3574 patients (44.8%) died, 1342 (16.8%) from cardiovascular causes, during a median follow-up of 2.7 years. Survival analysis in a propensity-score matched study population showed lower all-cause mortality for cinacalcet-treated versus untreated patients in subsets of patients characterized by younger age, low prevalence of diabetes, intact parathyroid hormone levels of 300 to 599 pg/mL, and concomitant therapy with vitamin D and phosphate binders.